QuidelOrtho Corporation ( QDEL ) NASDAQ Global Select

Cena: 30.19 ( 0.03% )

Aktualizacja 07-03 22:00
NASDAQ Global Select
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 7 100
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 72%
Ilość akcji: 66 818 700
Debiut giełdowy: 1991-02-01
WWW: https://www.quidelortho.com
CEO: Mr. Brian J. Blaser
Adres: 9975 Summers Ridge Road
Siedziba: 92121 San Diego
ISIN: US2197981051
Opis firmy:

Quidelortho Corporation koncentruje się na rozwoju i produkcji technologii testowania diagnostycznego w kontinuum potrzeb w zakresie badań zdrowotnych. Firma działa za pośrednictwem laboratoriów, medycyny transfuzji, jednostek biznesowych w zakresie opieki i diagnostyki molekularnej. Labs Business Unit zapewnia instrumenty i testy laboratoryjne chemii klinicznej, które mierzą docelowe chemikalia w płynach ciała w celu oceny zdrowia i leczenia klinicznego pacjentów; Instrumenty i testy laboratoryjne immunoassa, które mierzą białka, ponieważ działają one jako antygeny w rozprzestrzenianiu się choroby, przeciwciała w odpowiedzi immunologicznej pobudzonej przez chorobę lub markery właściwej funkcji narządów i zdrowia; testowanie produktów w celu wykrycia i monitorowania postępu choroby w spektrum obszarów terapeutycznych; oraz wyspecjalizowane rozwiązania diagnostyczne. Jednostka biznesowa medycyny transfuzji oferuje instrumenty immunohematologiczne i testy stosowane do pisania krwi w celu zapewnienia kompatybilności pacjenta w transfuzji krwi; oraz instrumenty i testy przesiewowe dawcy stosowane do badań przesiewowych krwi i w osoczu pod kątem chorób zakaźnych. Jednostka biznesowa w punkcie opieki zapewnia testy, aby zapewnić szybkie wyniki w kontinuum ustawień punktu pielęgnacyjnego. Jednostka biznesowa diagnostyki molekularnej oferuje termocyklery reakcji łańcuchowej polimerazy; oraz analizy i systemy wzmocnienia. Firma sprzedaje swoje produkty bezpośrednio użytkownikom końcowym za pośrednictwem sprzedaży bezpośredniej; oraz za pośrednictwem sieci dystrybutorów do profesjonalnego stosowania w biurach lekarzy, szpitali, laboratoriów klinicznych, laboratoriów referencyjnych, klinik pilnej opieki, uniwersytetów, klinik detalicznych, apteki, centrów badań wellness, banków krwi i centrów donistrów, a także w przypadku indywidualnych, nieprofesjonalnych i niedozwolonych. Działa w Ameryce Północnej, Europie, na Bliskim Wschodzie, Afryce, Chinach i na arenie międzynarodowej. Firma została założona w 1979 roku i ma siedzibę w San Diego w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 2 041 625 921
Aktywa: 6 801 100 000
Cena: 30.19
Wskaźnik Altman Z-Score: 0.1
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -5.8
Ilość akcji w obrocie: 72%
Średni wolumen: 1 716 455
Ilość akcji 67 625 900
Wskaźniki finansowe
Przychody TTM 2 815 700 000
Zobowiązania: 3 614 400 000
Przedział 52 tyg.: 23.77 - 49.45
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -5.2
P/E branży: 29.9
Beta: 0.116
Raport okresowy: 2025-07-30
WWW: https://www.quidelortho.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Robert J. Bujarski J.D. Executive Vice President & Chief Operating Officer 961 261 1969
Mr. Joseph M. Busky CPA Chief Financial Officer 890 626 1968
Mr. Michael S. Iskra Executive Vice President & Chief Commercial Officer 870 929 1970
Ms. Michelle A. Hodges J.D. Senior Vice President, General Counsel & Corporate Secretary 1 795 965 1963
Dr. Werner Kroll Ph.D. Senior Vice President of Research & Development 1 026 686 1957
Ms. Tamara A. Ranalli Molecular Diagnostics Business Unit Leader 0 1973
Mr. Brian J. Blaser President, Chief Executive Officer & Director 0 1965
Ruben Argueta Director of Investor Relations 0 0
Mr. William J. Ferenczy Point of Care Business Unit Leader 0 1956
Wiadomości dla QuidelOrtho Corporation
Tytuł Treść Źródło Aktualizacja Link
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-05-15 14:50:24 Czytaj oryginał (ang.)
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade) Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%. seekingalpha.com 2025-05-12 13:30:00 Czytaj oryginał (ang.)
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025. zacks.com 2025-05-08 17:10:54 Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen mode only. seekingalpha.com 2025-05-07 23:56:03 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago. zacks.com 2025-05-07 23:10:32 Czytaj oryginał (ang.)
QuidelOrtho Reports First Quarter 2025 Financial Results SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. “We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President an. businesswire.com 2025-05-07 20:05:00 Czytaj oryginał (ang.)
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins. zacks.com 2025-05-06 15:15:45 Czytaj oryginał (ang.)
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release. zacks.com 2025-05-01 12:30:38 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy? QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-30 15:06:08 Czytaj oryginał (ang.)
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-24 17:15:50 Czytaj oryginał (ang.)
QuidelOrtho to Report First Quarter 2025 Financial Results SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at. businesswire.com 2025-04-23 20:30:00 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains? QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2025-04-10 16:35:40 Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now QDEL continues to witness growth on the back of its strong product portfolio. zacks.com 2025-04-09 18:35:36 Czytaj oryginał (ang.)
QuidelOrtho Unveils Results Manager System to Streamline Testing QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care. zacks.com 2025-03-14 13:05:31 Czytaj oryginał (ang.)
QuidelOrtho® Introduces Results Manager™ System SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. The QuidelOrtho Results Manager system. businesswire.com 2025-03-10 11:00:00 Czytaj oryginał (ang.)
Why QuidelOrtho Stock Bounced More Than 4% Higher Today Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encouraged market traded the company's shares up by more than 4% in response. fool.com 2025-02-13 20:19:00 Czytaj oryginał (ang.)
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024. zacks.com 2025-02-13 13:57:12 Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode. seekingalpha.com 2025-02-12 21:50:17 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates QuidelOrtho (QDEL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $1.17 per share a year ago. zacks.com 2025-02-12 20:41:07 Czytaj oryginał (ang.)
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. “We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025,” said Brian J. Blaser, President and Chief Execu. businesswire.com 2025-02-12 18:05:00 Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now QDEL continues to witness growth on the back of its strong product portfolio. zacks.com 2025-01-30 13:56:17 Czytaj oryginał (ang.)
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues QDEL's preliminary fourth-quarter revenues align with the company's expectations. zacks.com 2025-01-14 14:50:22 Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory. prnewswire.com 2025-01-07 02:48:00 Czytaj oryginał (ang.)
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company's presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast. businesswire.com 2024-12-31 09:00:00 Czytaj oryginał (ang.)
QuidelOrtho Announces Appointment of Two Independent Directors to its Board SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the “Board”), effective December 6, 2024. These appointments align with QuidelOrtho's commitment to maintaining a strong, independent Board with the ri. businesswire.com 2024-12-10 09:00:00 Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now QDEL continues to witness growth on the back of its strong product portfolio. zacks.com 2024-12-04 15:30:29 Czytaj oryginał (ang.)
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares. benzinga.com 2024-11-20 17:08:36 Czytaj oryginał (ang.)
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. benzinga.com 2024-11-20 10:06:51 Czytaj oryginał (ang.)
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selli. businesswire.com 2024-11-19 23:05:00 Czytaj oryginał (ang.)
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selling Stockholder will rec. businesswire.com 2024-11-19 18:54:00 Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory. prnewswire.com 2024-11-13 14:39:00 Czytaj oryginał (ang.)
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter. zacks.com 2024-11-08 15:21:18 Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript QuidelOrtho Corporation (NASDAQ:QDEL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President, Investor Relations Brian Blaser – President and Chief Executive Officer Joe Busky – Chief Financial Officer Conference Call Participants Andrew Brackmann – William Blair Jack Meehan – Nephron Research Bill Bonello – Craig-Hallum Patrick Donnelly – Citi Andrew Cooper – Raymond James Jose Ricardo Moreno – RBC Capital Markets Casey Woodring – JPMorgan Operator Welcome to the QuidelOrtho Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode. seekingalpha.com 2024-11-07 22:54:26 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates QuidelOrtho (QDEL) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.90 per share a year ago. zacks.com 2024-11-07 21:41:06 Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. globenewswire.com 2024-10-31 16:17:00 Czytaj oryginał (ang.)
QuidelOrtho to Participate in Three Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part. businesswire.com 2024-10-28 09:00:00 Czytaj oryginał (ang.)
QuidelOrtho to Report Third Quarter 2024 Financial Results SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginni. businesswire.com 2024-10-17 11:00:00 Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now QDEL's strong product portfolio raises optimism about the stock. zacks.com 2024-10-08 17:42:10 Czytaj oryginał (ang.)
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key. businesswire.com 2024-09-10 11:00:00 Czytaj oryginał (ang.)
Why QuidelOrtho Stock Blasted 10% Higher Today An analyst became notably more bullish on the diagnostics company's prospects. He upgraded his recommendation from hold to buy. fool.com 2024-09-05 21:25:23 Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now QDEL's strong product portfolio raises optimism about the stock. zacks.com 2024-09-03 14:46:11 Czytaj oryginał (ang.)
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio. zacks.com 2024-08-30 16:56:20 Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue? QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-08-30 16:36:29 Czytaj oryginał (ang.)